Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs is strategically focused on advancing its GEO-MVA vaccine candidate, supported by regulatory alignment and completion of clinical supply manufacturing, placing the company in a potentially accelerated path to late-stage development of orthopoxvirus vaccines. The company's balance sheet is the key limiting factor and likely to remain a focus until additional capital or strategic support is secured. Despite this, the company plans to have a pivotal execution year in 2026 with multiple clinical readouts, including for GEO-CM04S1 and Gedeptin, positioning it for potential late-stage catalysts.

Bears say

Geovax Labs is currently facing challenges in its pipeline, with GEO-MVA being the primary focus despite facing delays in data results and a planned immunobridging study in 2026. The company's decision to implement a 1-for-10 reverse stock split in 2023 could signal previous weaknesses and result in heightened dilution risks for potential future capital raises, causing investor sensitivity. Additionally, while the company has multiple programs approaching value-inflection points, including Gedeptin's combination study in head and neck cancer and GEO-CM04S1's Phase 2 data in COVID-19, these are unlikely to have a significant impact on valuation in the near term. Furthermore, the company's ability to manufacture its products may be hindered by historical supply constraints.

Geovax Labs (GOVX) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Hold based on their latest research and market trends.

According to 1 analysts, Geovax Labs (GOVX) has a Hold consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.